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ABSTRACT – Context - Desmoid tumors constitute one of the most important extraintestinal manifestations of familial adenomatous 
polyposis. The development of desmoids is responsible for increasing morbidity and mortality rates in cases of familial adenomatous 
polyposis. Objectives - To evaluate the occurrence of desmoid tumors in familial adenomatous polyposis cases following prophylactic 
colectomy and to present patient outcome. Methods - Between 1984 and 2008, 68 patients underwent colectomy for familial adenomatous 
polyposis at the School of Medical Sciences Teaching Hospital, University of Campinas, SP, Brazil. Desmoid tumors were found 
in nine (13.2%) of these patients, who were studied retrospectively by consulting their medical charts with respect to clinical and 
surgical data. Results - Of nine patients, seven (77.8%) were submitted to laparotomy for tumor resection. Median age at the time 
of surgery was 33.9 years (range 22-51 years). Desmoid tumors were found in the abdominal wall in 3/9 cases (33.3%) and in an 
intra-abdominal site in the remaining six cases (66.7%). Median time elapsed between ileal pouch-anal anastomosis and diagnosis 
of desmoid tumor was 37.5 months (range 14-60 months), while the median time between colectomy with ileorectal anastomosis 
and diagnosis was 63.7 months (range 25-116 months). In 6/9 (66.7%) patients with desmoid tumors, the disease was either under 
control or there was no evidence of tumor recurrence at a follow-up visit made a mean of 63.1 months later (range 12-240 months). 
Conclusions - Desmoid tumors were found in 13.2% of cases of familial adenomatous polyposis following colectomy; therefore, familial 
adenomatous polyposis patients should be followed-up and surveillance should include abdominal examination to detect signs and 
symptoms. Treatment options include surgery and clinical management with antiestrogens, antiinflammatory drugs or chemotherapy.
HEADINGS – Fibromatosis, abdominal. Adenomatous polyposis coli. Anastomosis, surgical. Colonic pouches.
INTRODUCTION
Desmoid tumors are mesenchymal neoplasms 
resulting from the proliferation of well-differentiated 
fibroblasts. They are benign, non-metastasizing 
fibrous masses; however, they are locally aggressive. 
Desmoids may occur sporadically or in association 
with familial adenomatous polyposis (FAP) and may 
be extraabdominal, intra-abdominal or located in the 
abdominal wall(21, 27). The etiology of these tumors is not 
completely clear, but in FAP patients, their development 
has been associated with mutations occurring beyond 
codon 1444 of the adenomatous polyposis coli (APC) 
gene(2, 16). In addition, other factors that have been 
identified as predictors of  desmoids in FAP cases 
include being female, previous abdominal surgery, 
pregnancy, exposure to oral contraceptives, a family 
history of desmoids and the presence of osteomas(2, 8, 12).
Although rare in the general population, with 
an annual incidence of  just 2-4 cases per million 
inhabitants, desmoid tumors are a common extracolonic 
manifestation of  FAP, with a prevalence of  10%-
20% in these patients(3, 8, 30). Patients with FAP have 
a 1000-fold increased risk of  developing desmoid 
tumors compared to the general population, and 
2% of  all cases of  desmoid tumors are associated 
with FAP(5, 11, 28).
Desmoid tumors are the second most common 
cause of  death in FAP patients after colorectal 
carcinoma. In view of this fact, surveillance to detect 
extracolonic manifestations assumes great importance 
in the follow-up of  patients who have undergone 
prophylactic colectomy for FAP(13, 14, 15, 32).
Treating desmoids surgically has been associated 
with high rates of tumor recurrence. Several medical 
approaches have been used, but no evidence-based 
management is currently available for the treatment of 
this neoplasm. The use of chemotherapy, antiestrogen 
therapy, nonsteroidal anti-inflammatory drugs and 
radiotherapy with or without surgical resection have all 
been reported, resulting in varying levels of success(9, 
10, 31, 35). The aim of the present study was to review the 
occurrence of desmoid tumors in FAP cases following 
prophylactic colectomy and to present patient outcome.
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METHODS
Between the years 1984 and 2008, 68 patients were 
submitted to colectomy for FAP at the School of Medical 
Sciences, Teaching Hospital of the University of Campinas 
(UNICAMP), SP, Brazil. Fifty-six (82.4%) of these patients 
were submitted to proctocolectomy with ileal pouch-anal 
anastomosis (IPAA), 10 (14.7%) to colectomy with ileorectal 
anastomosis and 2 (2.9%) to proctocolectomy with permanent 
ileostomy. Desmoid tumors were found in 9 (13.2%) of 
these patients, who were then studied retrospectively using 
data from their medical records. Data were obtained on 
the procedure used in colon surgery, on the postoperative 
follow-up presentation of the desmoid tumor, treatment, 
and patient outcome.
The study was carried out at the Coloproctology Unit, 
UNICAMP, and additional data were obtained from the files 
of the Department of Pathology, UNICAMP.
RESULTS
Six (66.7%) of the nine patients who had desmoid tumors 
were female. The diagnosis of desmoid tumor was made based 
on clinical symptoms, the presence of an abdominal tumor 
and the results of abdominal ultrasonography or computed 
tomography during post-operative follow-up. In one of the 
patients, diagnosis was made during laparotomy, which had 
been required because of a small bowel obstruction. Seven 
patients (77.8%) were submitted to laparotomy for tumor 
resection, their median age at the time of the surgery being 
33.9 years (range 22-51 years). Another two patients of 35 
and 38 years of  age, respectively, were not submitted to 
surgery for the removal of their abdominal desmoids due to 
their clinical condition and the impossibility of resection, 
as revealed on computed tomography images. One of these 
two patients was treated with tamoxifen and a nonsteroidal 
anti-inflammatory drug (NSAID), resulting in a decrease in 
the size of the tumor and control of the disease. In the other 
case, the desmoid tumor continued to grow despite the use 
of tamoxifen; however, no further information was available 
because the patient was lost-to-follow-up. It is interesting to 
note that in this series none of the patients were related and 
there was no association with pregnancy.
In three of the nine patients (33.3%), the desmoid tumor 
was found in the abdominal wall (Figure 1), while the tumor 
was intra-abdominal in the remaining six (66.7%) (Figure 
2). In one of the seven patients who underwent laparotomy, 
complete removal of the tumor proved impossible, however, 
diagnosis was confirmed in a biopsy specimen. This patient 
is currently using tamoxifen and NSAIDs; however, response 
is poor. In four patients who were submitted to resection, no 
evidence of a recurrent desmoid tumor was found at a median 
time of 43.3 months following surgery (range 15-60 months). 
With respect to the other two patients, one had a recurrence 
following surgery and in this case resection was impossible, 
while the other, whose tumor was in the abdominal wall, 
developed a recurrence in the form of a pelvic desmoid tumor, 
which was treated with Sulindac®, resulting in a reduction 
in tumor size. This patient has been followed-up for over 15 
years. Ureteric obstruction did not occur in any of these cases.
The median time elapsed between IPAA and diagnosis of 
the desmoid tumor was 37.5 months (range 14-60 months), 
whereas the median time between colectomy and ileorectal 
anastomosis to diagnosis of the desmoid tumor was 63.7 months 
(range 25-116 months). One patient, who was submitted to 
proctocolectomy including total removal of the anal canal 
because of rectal cancer associated with FAP, developed a 
desmoid tumor 12 months after surgery. In another patient, 
a desmoid tumor had been found in the abdominal wall 12 
years prior to colectomy for FAP. The characteristics of the 
abdominal desmoid tumors detected in these nine patients 
are summarized in Table 1.
FIGURE 1. A desmoid tumor in the abdominal wall
FIGURE 2. Intra-abdominal desmoid tumor
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Finally, of  these nine patients, either the disease was 
controlled or no evidence of a recurrence of the desmoid 
tumor was detected in six cases (66.7%) after a mean follow-
up of 63.1 months (range 12-240 months). Seven patients 
(77.8%) remain in treatment, consisting principally of the 
use of tamoxifen and/or NSAIDs.
Microscopically, the lesions consisted of bland, spindle-
shaped cells evenly deposited in a collagenous stroma with 
myxoid change (Figure 3).





Time up to desmoid appearance





1 28 F 14 * Resection None No recurrence 2 years later
2 30 F 28 ** Resection with enteric
anastomosis
Tamoxifen; Celecoxib® No recurrence 5 years later
3 22 F 25 ** Resection with enteric
anastomosis
Tamoxifen; Celecoxib® Recurrence, 
not resected; slowly growing 
tumor; 3 years of follow-up
4 43 M 60 ** Resection None No recurrence 5 years later
5 27 F 146 * Resection Sulindac® Pelvic recurrence; not resected. 
No progression; 20 years of 
follow-up
6 26 F 50 months before ** No resection Tamoxifen Progression; lost to follow-up
7 34 M 48 months before ** No resection Tamoxifen; Celecoxib® No progression 4 years later
8 36 F 116 * Resection Sulindac® No recurrence 4 years later
9 57 M 12 ** No resection (only 
biopsy)
Tamoxifen; Celecoxib® Slowly growing desmoid; 1 year 
of follow-up
* Desmoid tumor in the abdominal wall
** Desmoid tumor in the mesentery
FIGURE 3. A) Panoramic view of mesenteric fibromatosis, forming a mass involving the wall of the small bowel and mesenteric fat. B) 
Low-power view of mesenteric fibromatosis showing uniform fibrocollagenous growth infiltrating the wall and attached to the muscular 
coat of the small bowel (*). C), D), E) Orderly arrangement and interlacing bundles of uniform spindled fibroblast proliferation, separated 
by varying amounts of collagen and mucoid material in mesenteric fibromatosis
DISCUSSION
Desmoid tumors represent one of the most significant 
causes of  the morbidity and mortality that affects FAP 
patients following colectomy. For this reason, an analysis 
was performed of cases of desmoid tumors associated with 
FAP, including their treatment and outcome, in order to 
acquire further knowledge on these tumors and study the 
clinical management of this disease. The incidence of desmoid 
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tumors is relatively high in FAP. The present findings show 
that 13.2% of patients (9/68) developed desmoid tumors 
in the abdominal wall or intra-abdominally, while 66.7% 
(6/9) showed no evidence of any recurrence or their disease 
remained under control.
Gurbuz et al.(8) reported a rate of  10% of  desmoid 
tumors in FAP patients, while Sagar et al.(28) reported a rate 
of  5.6%. Lefevre et al.(16) reported a rate of  11.3% in their 
review of  442 patients with FAP, the only modifiable factor 
being the type of  surgical procedure; however, this was not 
found to have any significant effect on the risk of  developing 
a desmoid tumor and did not modify the management of 
FAP patients(16).
Genetic data is helpful in defining patients with a higher 
risk for desmoids, who may benefit from specific prevention 
therapy. Bertario et al.(2) found a rate of  11.9% of  desmoid 
tumors in their FAP population and reported that APC 
mutations beyond codons 1444 and 1309 were indicative of 
a 12-fold and 17-fold increased risk, respectively. However, 
Stuart et al.(30) found no correlation between APC gene 
mutation and a predisposition to developing a desmoid 
tumor. More recently, Lips et al.(17) associated mutations in 
both the APC and beta-catenin genes with the formation of 
desmoid tumors. Studies have reported biallelic mutations in 
the human MutY homolog (MYH) gene in 29% of  patients 
with FAP; therefore mutation analysis of  this gene should 
be considered(22). Unfortunately, no genetic testing results 
were available for the present review. Family surveillance is 
very important and, although no cases of  desmoid tumors 
in the same family were found in the present study, we have 
broadened surveillance criteria by including annual abdominal 
ultrasonography or abdominal computed tomography scan 
in their follow-up. The pathogenesis is not completely clear 
and desmoid tumors have become the greatest remaining 
challenge in the treatment of  FAP after the management 
of  duodenal adenomas and colorectal cancer.
High doses of tamoxifen, a selective estrogen receptor 
modulator, and NSAIDs such as Sulindac® or Celecoxib® 
are recommended as the primary treatment for patients with 
FAP-associated desmoid tumors(10, 33). However, primary 
surgery, whenever possible, has been indicated for small, 
well-defined tumors with clear margins on image findings. 
Drugs help prevent recurrences and control progression of 
the disease in these cases. These tumors often involve the 
small bowel mesentery, making complete removal difficult or 
impossible, and they may also involve the ureters or superior 
mesenteric veins, increasing morbidity and mortality. Small 
bowel obstruction is a common occurrence and was found in 
the present sample in those patients who had intra-abdominal 
tumors(24, 29). In this series, there were no cases of complications 
due to ureteric obstruction, although this has been reported 
in rare cases of abdominal desmoid tumors(25, 26).
Resection in cases of recurrent disease is frequently a more 
aggressive procedure than that used for the initial desmoid and 
may involve removal of a varying length of the small bowel(7, 
19). In the current sample population, removal of the entire 
tumor proved impossible in two patients who were submitted 
to surgery for recurrence of an abdominal desmoid. In these 
cases, drugs (tamoxifen, Sulindac®) were used to control the 
disease. Although resection was not possible, the patients are 
well and are being managed clinically. Chemotherapy should 
be considered for the treatment of aggressive desmoids in 
which there is a risk of morbidity or mortality if  surgery 
were performed, and also for the management of desmoid 
tumors that fail to respond to tamoxifen or NSAIDs(1, 18, 
25). None of the patients in the present sample has required 
chemotherapy up to the present moment.
Although none of  the female patients in this series 
developed desmoid tumors during pregnancy, this condition 
has been reported to improve the course of  abdominal 
desmoid tumors in FAP due to the fact that they may be 
estrogen-dependent(4, 20).
In relation to the type of  colon surgery and the appearance 
of  a desmoid tumor, Nieuwenhuis et al.(23) reported on 
a cohort in which they found a rate of  9% of  desmoid 
tumors and Von Roon et al.(34) also focused on this point 
of  discussion. These authors concluded that there are no 
significant differences in the diagnosis rates of  desmoid 
tumors when IPAA and ileorectal anastomosis are compared, 
however, they recommended IPAA for patients with a positive 
family history of  desmoids, since in their experience, it 
was impossible to convert ileorectal anastomosis to IPAA 
in some patients with FAP, as proved necessary when the 
presence of  desmoids was detected(6, 34).
CONCLUSIONS
FAP patients must be followed up closely and abdominal 
examination should be performed to detect any signs or 
symptoms of an abdominal tumor. In most patients, surgery 
is used to manage any obstructive complications and for the 
treatment of small, simple desmoid tumors or those shown 
as having clear margins on computed tomography scans. 
Alternative therapies with antiestrogens and anti-inflammatory 
drugs and chemotherapy must be considered in the case of 
aggressive desmoids or in patients in whom the preoperative 
surgical risk is considerable.
Despite current knowledge, management of desmoid tumors 
remains controversial with regard to decisions concerning 
surgery and adjuvant therapy. Consequently, more research is 
required to develop alternative treatment strategies to decrease 
the morbidity and mortality associated with desmoids in FAP 
patients. Further studies will be necessary to improve clinical 
management in these cases.
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